Amgen Presents P-III (CodeBreaK 200) Trial Results of Lumakras/Lumykras (sotorasib) for Non-Small Cell Lung Cancer at ESMO 2022
Shots:
- The P-III (CodeBreaK 200) trial evaluates sotorasib vs docetaxel in 345 patients with KRAS G12C-mutated NSCLC. Eligible patients have previously undergone treatment for LA, incurable, or m-KRAS G12C-mutated NSCLC
- The results showed an improved PFS (25% vs 10%) @1yr. in heavily pre-treated patients & higher ORR with double the response rates (28% vs 13%) along with consistent benefit across other efficacy 2EPs incl. improved DCR (83% vs 60%), OS was not different b/w treatment arms, grade ≥3 TRAEs (33% vs 40%) & serious TRAEs (11% vs 23%)
- The company will share the results with regulatory authorities globally. The therapy is being studied in multiple P-I studies as monothx. & in combination therapy in multiple advanced solid tumors
Ref: PRNewswire | Image: Amgen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
